Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 9226 - 9250 of 10617 in total
The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes. [PubChem]
Experimental
Matched Iupac: … (2R,3S)-2-amino-3-(phosphonooxy)butanoic acid …
Experimental
Matched Iupac: … (2R)-2-amino-3-[(carbamoylmethyl)sulfanyl]propanoic acid …
Experimental
Matched Iupac: … (2R)-2-amino-3-[(dimethylarsoryl)sulfanyl]propanoic acid …
An intravenous anesthetic that has been used for rapid induction of anesthesia and for maintenance of anesthesia of short duration. (From Martindale, The Extra Pharmacopoeia, 30th ed, p918)
Experimental
Matched Iupac: … propyl 2-{4-[(diethylcarbamoyl)methoxy]-3-methoxyphenyl}acetate …
Prifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome .
Experimental
Matched Iupac: … 3-(diphenylmethylidene)-1,1-diethyl-2-methylpyrrolidin-1-ium …
Experimental
Matched Iupac: … 3-[bis(thiophen-2-yl)methylidene]-1-methylpiperidine …
Experimental
Matched Iupac: … (59Fe)iron(3+) ion 2-hydroxypropane-1,2,3-tricarboxylate …
Experimental
Matched Iupac: … iron(3+) ion sodium 2-oxidopropane-1,2,3-tricarboxylate …
Experimental
Matched Iupac: … bismuth(3+) ion tetrabromobenzene-1,2-bis(olate) hydroxide …
Experimental
Matched Iupac: … zinc(2+) bis((2R)-2-acetamido-3-sulfanylpropanoate) …
Mesdopetam is under investigation in clinical trial NCT04435431 (A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia).
Investigational
Matched Iupac: … [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine …
Suratadenoturev is a gene-modified oncolytic adenovirus expressing the telomerase reverse transcriptase gene.
Investigational
Doramapimod is a P38 MAP kinase inhibitor.
Investigational
Matched Iupac: … 3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea …
Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
Investigational
Matched Iupac: … 4-carbamimidoyl-N-(3-{[(2S)-1-(2,4-dichloro-3-{[(2,4-dimethylquinolin-8-yl)oxy]methyl}benzenesulfonyl …
Investigational
Matched Iupac: … (2S,3R,5S)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl (2S)-2-amino-3-methylbutanoate …
Investigational
Matched Iupac: … 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4- …
Analog of prostaglandin F2 alpha.
Vet approved
Matched Iupac: … methyl 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hepta-4,5-dienoate …
Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study,...
Investigational
Matched Iupac: … N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl …
VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease).
Investigational
Matched Iupac: … (2R,4S)-4-(3-chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl …
Investigational
Matched Iupac: … 2-{4-[(9R)-9-hydroxy-2-(3-hydroxy-3-methylbutoxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl …
Cotadutide is under investigation in clinical trial NCT03444584 (Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Subject With Type 2 Diabetes).
Investigational
Matched Iupac: … -4-yl)propanamido]-3-hydroxypropanamido]-4-carbamoylbutanamido]acetamido}-3-hydroxybutanamido]-3-phenylpropanamido ... (2S)-4-{[(5S)-5-[(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S,3R)-2-{2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol ... -2-(4-hydroxyphenyl)ethyl]carbamoyl}-3-carboxypropyl]carbamoyl}-2-hydroxyethyl]carbamoyl}pentyl]carbamoyl ... )-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-4-carbamimidamido-1-{[(1S)-1-{[(1S)-4-carbamimidamido-1-{[(1S)- ... ]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-carboxypropanamido]-5-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S …
Experimental
Matched Iupac: … 3-{[(4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-2-oxo-3-({3-[(1,3-thiazol-2-yl)carbamoyl]phenyl}methyl)- …
Experimental
Matched Name: … [1-(4-Fluorobenzyl)Cyclobutyl]Methyl (1s)-1-[Oxo(1h-Pyrazol-5-Ylamino)Acetyl]Pentylcarbamate …
Matched Iupac: … {1-[(4-fluorophenyl)methyl]cyclobutyl}methyl N-[(2S)-1-oxo-1-[(1H-pyrazol-5-yl)carbamoyl]hexan-2-yl]carbamate …
ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Investigational
Matched Iupac: … (5S)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol …
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Matched Iupac: … N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide …
Displaying drugs 9226 - 9250 of 10617 in total